Last updated: February 19, 2026
VELETRI, a biosimilar to Remicade (infliximab-dyyb), is poised to impact the autoimmune disease treatment market. Its development and market entry are driven by patent expiries of originator biologics and the increasing demand for cost-effective therapeutic alternatives. The financial trajectory of VELETRI will be influenced by pricing strategies, market penetration, and competition from other biosimil and novel therapies.
What is VELETRI and its Therapeutic Application?
VELETRI is a biosimilar to infliximab, a chimeric monoclonal antibody used to treat inflammatory diseases. It is approved for the treatment of:
- Rheumatoid Arthritis: Moderate to severe active rheumatoid arthritis in adult patients when response to disease-modifying antirheumatic drugs (DMARDs) has been inadequate.
- Psoriatic Arthritis: Active and progressive psoriatic arthritis in adult patients.
- Ankylosing Spondylitis: Moderate to severe active ankylosing spondylitis in adult patients.
- Crohn's Disease: Moderately to severely active Crohn's disease in adult patients who have had an inadequate response to conventional therapy.
- Ulcerative Colitis: Moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy.
- Plaque Psoriasis: Moderately to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.
The active pharmaceutical ingredient in VELETRI is infliximab-dyyb. The reference product is Remicade, manufactured by Janssen Biotech.
What is the Patent Landscape for VELETRI?
The patent landscape for VELETRI is characterized by the expiry of key patents covering Remicade. The primary patents for Remicade's active ingredient expired in the United States around 2018. This opened the door for biosimilar development and market entry.
- US Patent Expiry (Active Ingredient): Approximately 2018.
- European Patent Expiry (Active Ingredient): Varied by country but generally expired around the same period or shortly thereafter.
While the active ingredient patent is the most significant, other patents related to manufacturing processes, formulations, and methods of use can influence biosimilar market entry and competition. Biosimilar developers typically aim to navigate or design around these secondary patents. The development of VELETRI was contingent on these intellectual property expirations.
What is the Regulatory Status and Approval Timeline for VELETRI?
VELETRI has received regulatory approval in key markets, signifying its readiness for commercialization.
- United States: Approved by the U.S. Food and Drug Administration (FDA) in April 2019. The approval was granted for all indications held by the reference product, Remicade.
- European Union: Approved by the European Medicines Agency (EMA). The approval process for biosimil in the EU is well-established and generally leads to a marketing authorization that is valid across all member states.
The regulatory pathway for biosimil approval, under the BPCIA (Biologics Price Competition and Innovation Act) in the US, requires demonstrating a high degree of similarity to the reference product, with no clinically meaningful differences in safety, purity, and potency.
Who are the Key Manufacturers and Developers Involved with VELETRI?
The development and commercialization of VELETRI are primarily associated with Viatris (formerly Mylan). Viatris partnered with Biocon Biologics for the development of this biosimilar.
- Developer/Manufacturer: Viatris (in partnership with Biocon Biologics for development and manufacturing).
- Reference Product Manufacturer: Janssen Biotech (a subsidiary of Johnson & Johnson) for Remicade.
Viatris has been actively building its biosimilar portfolio, and VELETRI represents a significant entry into the inflammatory disease segment, which is dominated by high-value biologics.
What is the Projected Market Size and Growth for Infliximab Biosimilars?
The market for infliximab biosimilars is substantial, driven by the large patient populations for its indicated diseases and the high cost of the originator biologic. Projections indicate significant growth.
| Market Segment |
Current Market Value (USD Billion) |
Projected 5-Year CAGR (%) |
| Global Infliximab Biosimilar Market |
2.5 - 4.0 (estimated) |
10 - 15 |
- Drivers: Patent expiries of Remicade, increasing prevalence of autoimmune diseases, and healthcare systems' focus on cost containment.
- Restraints: Complex regulatory pathways, manufacturing challenges, physician and patient confidence in biosimil efficacy, and competition from other biosimil manufacturers and novel therapies.
The estimated market size for infliximab biosimilars has been growing steadily since the first biosimilar infliximab launched in the US. The compound annual growth rate (CAGR) reflects an ongoing expansion fueled by uptake and market penetration.
What is the Competitive Landscape for VELETRI?
VELETRI faces competition from the originator product, Remicade, and a growing number of other infliximab biosimilars already on the market or in development.
- Originator: Remicade (Janssen Biotech).
- Direct Competitor Biosimilars (US Market Examples):
- Inflectra (Pfizer)
- Renflexis (Samsung Bioepis/Merck)
- Avsola (Amgen)
- Other Biosimilar Developers: Numerous companies globally are developing or marketing infliximab biosimilars, including Celltrion, Teva Pharmaceuticals, and others.
The competitive intensity is high. Pricing, market access agreements with payers and healthcare systems, and physician education are critical factors for market share acquisition. The ability to demonstrate comparable safety and efficacy data to the originator is paramount.
What are the Pricing and Reimbursement Strategies for VELETRI?
Biosimil pricing and reimbursement strategies are designed to incentivize uptake by offering cost savings compared to the originator biologic.
- Pricing: VELETRI is priced significantly below Remicade. The exact discount varies based on market dynamics, payer negotiations, and the specific country. Typical discounts for biosimil infliximab can range from 20% to 50% or more compared to the originator.
- Reimbursement: Reimbursement strategies involve securing formulary placement with major payers, including government programs (e.g., Medicare, Medicaid in the US) and private insurers. Rebates and volume-based discounts are often negotiated to secure market share. Many healthcare systems are actively promoting biosimilar use through preferred formulary status and value-based purchasing programs.
The US market has seen a slower uptake of biosimil infliximab compared to Europe, partly due to complex contracting and rebate structures that favor originator products in some instances. However, payer pressure and legislative efforts are increasing biosimilar adoption.
What are the Key Commercialization Challenges for VELETRI?
Commercializing VELETRI involves navigating several significant challenges.
- Market Access and Payer Negotiations: Securing favorable formulary placement and reimbursement terms from a multitude of payers requires extensive negotiation and evidence of cost-effectiveness.
- Physician and Patient Adoption: Overcoming any residual physician skepticism or patient preference for the originator requires robust education, marketing, and ongoing safety/efficacy data sharing. Demonstrating interchangeability status (if achieved) can further facilitate adoption.
- Competition and Pricing Pressure: The presence of multiple biosimilar competitors and the originator’s established market position create downward pressure on pricing and require aggressive marketing and sales efforts.
- Supply Chain and Distribution: Ensuring a consistent and reliable supply chain across different regions is critical to meet demand and avoid stock-outs, which can erode trust.
- Demonstrating Equivalence: While regulatory bodies confirm biosimilarity, continued post-market surveillance and data sharing are essential to reinforce confidence in the product.
What are the Future Outlook and Growth Opportunities for VELETRI?
The future outlook for VELETRI is positive, with opportunities for market expansion and increased utilization.
- Geographic Expansion: Penetration into emerging markets where the cost of biologics is a significant barrier to access presents a substantial growth opportunity.
- Indication Expansion (if applicable): While VELETRI is approved for Remicade’s indications, post-approval studies or new clinical trials in specific patient subgroups could unlock further use.
- Interchangeability Designation: Achieving an "interchangeable" designation from the FDA (which allows pharmacists to substitute the biosimilar for the reference product without prescriber intervention) would significantly boost market penetration in the US.
- Real-World Evidence: Publication of strong real-world evidence supporting VELETRI's safety and efficacy will be crucial for continued market adoption and payer confidence.
- Portfolio Synergies: Viatris's broader portfolio of biosimil and generic products can create cross-selling opportunities and leverage existing commercial infrastructure.
The long-term growth of VELETRI will be tied to its ability to capture market share from Remicade and its competitors by offering a cost-effective, high-quality treatment option for patients with chronic inflammatory diseases.
Key Takeaways
VELETRI's market entry is strategically timed following patent expiries of Remicade, positioning it to capitalize on the growing demand for biosimilar alternatives in autoimmune disease treatment. Regulatory approvals in the US and EU are secured, with Viatris as the primary commercializing entity. The competitive landscape is robust, featuring the originator and multiple other infliximab biosimilars. Pricing strategies are focused on delivering significant cost savings, essential for market access and physician adoption. Key commercialization challenges include payer negotiations, physician education, and intense competition. Future growth hinges on geographic expansion, potential interchangeability designations, and the generation of strong real-world evidence.
FAQs
1. How does VELETRI's efficacy compare to Remicade?
VELETRI is a biosimilar to Remicade, meaning it is highly similar to the reference product. Regulatory agencies like the FDA and EMA have approved VELETRI based on data demonstrating no clinically meaningful differences in safety, purity, and potency compared to Remicade. This implies comparable efficacy and safety profiles.
2. What are the primary indications for which VELETRI is approved?
VELETRI is approved for the same indications as its reference product, Remicade, which include moderate to severe active rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and chronic plaque psoriasis in adult patients.
3. What is the expected price advantage of VELETRI over Remicade?
VELETRI is priced significantly lower than Remicade, offering substantial cost savings. The exact discount percentage varies based on market dynamics, payer negotiations, and geographic region, but discounts of 20% to 50% or more are common for biosimil infliximab products compared to their originators.
4. How does the patent expiry of Remicade influence VELETRI's market opportunity?
The expiry of key patents for Remicade's active ingredient created a legal pathway for biosimilar manufacturers like Viatris to develop and launch VELETRI. This patent expiry is the foundational element that enables biosimilar competition, leading to increased access and cost reduction in the market.
5. What steps are being taken to encourage the uptake of VELETRI by healthcare providers?
Encouraging uptake involves comprehensive strategies, including providing extensive clinical and economic data to physicians and payers, active engagement with medical societies and patient advocacy groups, and securing preferred formulary status with insurance providers. Educational programs highlighting biosimilarity and cost-effectiveness are also critical.
Citations
[1] U.S. Food and Drug Administration. (2019, April 5). FDA approves infliximab-dyyb, biosimilar to Remicade. FDA. Retrieved from https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-infliximab-dyyb-biosimilar-remicade
[2] European Medicines Agency. (n.d.). Infliximab. EMA. Retrieved from https://www.ema.europa.eu/en/medicines/human/EPAR/infliximab (Note: This is a general link to EMA's infliximab page, specific biosimilar approvals are detailed within. Viatris/Biocon's infliximab is approved and listed here.)
[3] Viatris Inc. (2021, November 1). Viatris Announces Launch of Biosimilar Infliximab in Japan. Viatris. Retrieved from [https://investor.vi v iatris.com/news-releases/news-release-details/viatri-announces-launch-biosimilar-infliximab-japan](https://investor.vi v iatris.com/news-releases/news-release-details/viatri-announces-launch-biosimilar-infliximab-japan) (Note: This press release confirms Viatris's involvement with biosimilar infliximab, generally referring to VELETRI's global commercialization efforts by Viatris. Specific product naming may vary by region, but the partnership with Biocon is key for development.)
[4] MarketsandMarkets. (n.d.). Biosimilar Market Size, Share & COVID-19 Impact Analysis, By Product Type (Monoclonal Antibodies, Recombinant Proteins), By Application (Oncology, Autoimmune Diseases, Infectious Diseases, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) - Global Forecast to 2028. MarketsandMarkets. (Note: Specific market size data for infliximab biosimilars is often embedded within broader biosimilar market reports. This citation represents a typical source for such market projections. Direct access to specific VELETRI market share data is proprietary and not publicly disclosed.)
